Literature DB >> 22530350

Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with non alcoholic fatty liver disease.

R Aller1, D A De Luis, O Izaola, M González Sagrado, R Conde, D Pacheco, M C Velasco, H F Ovalle.   

Abstract

BACKGROUND: Some studies have pointed to a role of leptin and insulin resistance in pathogenesis of non alcoholic fatty liver disease (NAFLD). The aim of our study was to investigate the influence of Lys656Asn polymorphism LEPR gene on the histological changes, insulin resistance and leptin levels in overweight patients.
MATERIAL AND METHODS: A population of 76 patients with NAFLD was recruited in a cross sectional study. A biochemical analysis of serum was measured. Genotype of LEPR gene Lys656Asn was studied.
RESULTS: Nineteen patients (25%) had the genotype Lys656Asn and 4 patients genotype Asn656Asn (mutant type group) and 53 patients (69.7%) Lys656Lys (wild type group). Body mass index, weight, fat mass, waist circumference, waist to hip ratio, glucose levels and HOMA-IR were higher in mutant than wild type group. LEPR polymorphism is in any way related with liver lesions. The multivariate analysis adjusted by age, sex, BMI and genotype showed an independently association of lobular inflammation 4.19 (CI95%: 1.37-12.77), portal inflammation 1.97 (CI95%: 1.05-3.74) and steatosis 9.23 (CI95%: 1.47-57.83) with HOMA. Liver steatosis was associated with leptin levels (1.09 (CI95%: 1.06-1.18)), too.
CONCLUSION: Lys656Asn polymorphism of LEPR gene is associated with obesity parameters, insulin resistance and glucose levels in patients with NAFLD. In logistic regression analysis, only insulin resistance was associated with portal inflammation), lobular inflammation and steatosis; liver steatosis was related with leptin levels, too.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22530350

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

2.  Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease.

Authors:  Kayleigh L Wood; Michael H Miller; John F Dillon
Journal:  BMJ Open Gastroenterol       Date:  2015-02-17

Review 3.  Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review.

Authors:  Xiao-Lin Li; Jian-Qing Sui; Lin-Lin Lu; Nan-Nan Zhang; Xin Xu; Quan-Yong Dong; Yong-Ning Xin; Shi-Ying Xuan
Journal:  Lipids Health Dis       Date:  2016-03-10       Impact factor: 3.876

Review 4.  How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?

Authors:  Jake P Mann; Robert K Semple; Matthew J Armstrong
Journal:  Front Endocrinol (Lausanne)       Date:  2016-11-16       Impact factor: 5.555

Review 5.  New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Xu Zhang; Xuetao Ji; Qian Wang; John Zhong Li
Journal:  Protein Cell       Date:  2017-06-22       Impact factor: 14.870

6.  Association of polymorphisms in the leptin and leptin receptor genes with inflammatory mediators in patients with osteoporosis.

Authors:  Xing L Ye; Chun F Lu
Journal:  Endocrine       Date:  2013-03-05       Impact factor: 3.633

Review 7.  In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD).

Authors:  Giridhar Kanuri; Ina Bergheim
Journal:  Int J Mol Sci       Date:  2013-06-05       Impact factor: 5.923

8.  Leptin Receptor Gene Polymorphisms and the Risk of Non-Alcoholic Fatty Liver Disease and Coronary Atherosclerosis in the Chinese Han Population.

Authors:  Bai-Quan An; Lin-Lin Lu; Chen Yuan; Yong-Ning Xin; Shi-Ying Xuan
Journal:  Hepat Mon       Date:  2016-04-27       Impact factor: 0.660

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.